Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 8

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Feb 28, 2016; 22(8): 2601-2610
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2601

Table 1 Characteristics of patients receiving curative and palliative surgery n (%)

Variable	Curative surgery (n = 381)	Palliative surgery (n = 330)
Age (median [range])	60 [26-82]	58 [19-80]
Sex, male (%)	231 (60.6)	178 (53.9)
Presenting symptoms
Jaundice	267 (70.1)	240 (72.7)
Weight loss	26 (6.8)	22 (6.7)
Abdominal pain	24 (6.3)	28 (8.5)
Nausea and vomiting	20 (5.2)	17 (5.1)
General fatigue	44 (11.6)	23 (7.0)
Tumor markers (median [range])
Preoperative CA 19-9 level, U/mL	348 [0.6-1000]	539.9 [0.6-3015.2]
Preoperative CA 125 level, U/mL	19.84 [1.23-257.70]	33.94 [1.54-1598.00]
Preoperative CEA level, ng/mL	3.23 [0.20-65.51]	4.44 [0.47-1000.00]
Liver functions (median [range])
Preoperative TB level, umol/L	209.4 [7.1-586.3]	239.65 [1.90-805.70]
Preoperative ALT level, U/L	95 [10-967]	78.5 [6.0-1212.0]
Preoperative AST level, U/L	86 [14-1016]	87 [11-927]
Preoperative Albumin level, g/L	36.7 [18.7-51.8]	35.95 [21.30-72.50]
Preoperative hospital stay (median [range])	7 [2-44]	7 [3-48]
Total hospital stay (median [range])	19 [9-113]	16 [4-102]
Portal vein embolization	53 (13.9)
Biliary drainage	201 (52.8)
Estimated blood loss (median [range])	600 [50-2000]	348 [0.6-1000]
Bismuth-Corlette classification
Type I	95 (25.2)	16 (4.8)
Type II	92 (24.2)	59 (17.9)
Type IIIa or IIIb	102 (26.8)	102 (30.9)
Type IV	92 (24.2)	153 (46.4)

ALT: Alanine aminotransferase; AST: Aspartate transaminase; CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; TB: Total bilirubin.

Citation: Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016; 22(8): 2601-2610
URL: https://www.wjgnet.com/1007-9327/full/v22/i8/2601.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i8.2601

Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016; 22(8): 2601-2610 [PMID: 26937148 DOI: 10.3748/wjg.v22.i8.2601]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.